<?xml version="1.0" ?>
<document id="315f0a94d6ac0655e0e5defec4f9526641c76037">
  <chunk id="315f0a94d6ac0655e0e5defec4f9526641c76037.c0" text="Role of rhesus macaque IFITM3(2) in simian immunodeficiency virus infection of macaques">
    <entity charOffset="0-4" id="315f0a94d6ac0655e0e5defec4f9526641c76037.c0.e0" ontology_id="CHEBI_50906" text="Role" type="chemical"/>
  </chunk>
  <chunk id="315f0a94d6ac0655e0e5defec4f9526641c76037.c1" text="The interferon-induced transmembrane protein 3 (IFITM3) inhibits HIV and SIV infection at the stage of host cell entry. However, it is still unclear to what extent the antiviral activity of IFITM3 observed in cell culture translates into inhibition of HIV/SIV spread in the infected host. We have shown previously that although rhIFITM3 inhibits SIV entry into cultured cells, polymorphisms in the rhIFITM3 gene are not strongly associated with viral load or disease progression in SIV infected macaques. Here, we examined whether rhIFITM3(2), which is closely related to rhIFITM3 at the sequence level, exerts antiviral activity and whether polymorphisms in the rhIFITM3(2) gene impact the course of SIV infection. We show that expression of rhIFITM3(2) is interferon-inducible and inhibits SIV entry into cells, although with reduced efficiency as compared to rhIFITM3. We further report the identification of 19 polymorphisms in the rhIFITM3(2) gene. However, analysis of a well characterized cohort of SIV infected macaques revealed that none of the polymorphisms had a significant impact upon the course of SIV infection. These results and our previous work suggest that polymorphisms in the rhIFITM3 and rhIFITM3(2) genes do not strongly modulate the course of SIV infection in macaques.">
    <entity charOffset="37-44" id="315f0a94d6ac0655e0e5defec4f9526641c76037.c1.e0" ontology_id="CHEBI_16541" text="protein" type="chemical"/>
    <entity charOffset="168-177" id="315f0a94d6ac0655e0e5defec4f9526641c76037.c1.e1" ontology_id="CHEBI_22587" text="antiviral" type="chemical"/>
    <entity charOffset="611-620" id="315f0a94d6ac0655e0e5defec4f9526641c76037.c1.e2" ontology_id="CHEBI_22587" text="antiviral" type="chemical"/>
    <entity charOffset="996-1002" id="315f0a94d6ac0655e0e5defec4f9526641c76037.c1.e3" ontology_id="CHEBI_34935" text="cohort" type="chemical"/>
    <pair e1="315f0a94d6ac0655e0e5defec4f9526641c76037.c1.e0" e2="315f0a94d6ac0655e0e5defec4f9526641c76037.c1.e1" id="315f0a94d6ac0655e0e5defec4f9526641c76037.c1.p0" relation="true"/>
    <pair e1="315f0a94d6ac0655e0e5defec4f9526641c76037.c1.e0" e2="315f0a94d6ac0655e0e5defec4f9526641c76037.c1.e2" id="315f0a94d6ac0655e0e5defec4f9526641c76037.c1.p1" relation="true"/>
    <pair e1="315f0a94d6ac0655e0e5defec4f9526641c76037.c1.e0" e2="315f0a94d6ac0655e0e5defec4f9526641c76037.c1.e3" id="315f0a94d6ac0655e0e5defec4f9526641c76037.c1.p2" relation="true"/>
    <pair e1="315f0a94d6ac0655e0e5defec4f9526641c76037.c1.e1" e2="315f0a94d6ac0655e0e5defec4f9526641c76037.c1.e3" id="315f0a94d6ac0655e0e5defec4f9526641c76037.c1.p3" relation="true"/>
    <pair e1="315f0a94d6ac0655e0e5defec4f9526641c76037.c1.e2" e2="315f0a94d6ac0655e0e5defec4f9526641c76037.c1.e3" id="315f0a94d6ac0655e0e5defec4f9526641c76037.c1.p4" relation="true"/>
  </chunk>
  <chunk id="315f0a94d6ac0655e0e5defec4f9526641c76037.c2" text="PLOS ONE | https://doi.org/10.">
    <entity charOffset="5-8" id="315f0a94d6ac0655e0e5defec4f9526641c76037.c2.e0" ontology_id="CHEBI_58972" text="ONE" type="chemical"/>
  </chunk>
  <chunk id="315f0a94d6ac0655e0e5defec4f9526641c76037.c3" text="132 (6-907) Death with AIDS-related symptoms (%) 34 (72.3) Mamu-A1 ï¿½ 001 positive (%) 10 (21.2)"/>
</document>
